Keytruda Clears Low Hurdle In Stage III Melanoma
Merck & Co's Keytruda hits endpoint in KEYNOTE-054 as a monotherapy for high-risk patients but the low bar set by the placebo comparator means that rival Opdivo should keep its edge.
You may also be interested in...
The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.